

Resource Summary Report

Generated by SPARC SAWG on Jul 28, 2026

Akoya Biosciences: Phenolmager

RRID:SCR_023772

Type: Tool

Proper Citation

Akoya Biosciences: Phenolmager (RRID:SCR_023772)

Resource Information

URL: <https://www.akoyabio.com/phenoimager/instruments/>

Proper Citation: Akoya Biosciences: Phenolmager (RRID:SCR_023772)

Description: Digital pathology imager for spatial phenotyping. Provides accurate quantitative assessment of multiple immune phenotypes while capturing their tissue context and spatial distribution within tumor microenvironment.

Synonyms: Phenolmager

Resource Type: instrument resource

Keywords: USEdit, Akoya Biosciences, digital pathology imager, spatial phenotyping, multiple immune phenotypes assessment,

Availability: Restricted

Specification URL: https://raw.githubusercontent.com/SciCrunch/RRID-Instruments/main/PDF/SCR_023772.pdf

Resource Name: Akoya Biosciences: Phenolmager

Resource ID: SCR_023772

Record Creation Time: 20230711T050220+0000

Record Last Update: 20260725T191034+0000

Ratings and Alerts

No rating or validation information has been found for Akoya Biosciences: Phenolmager.

No alerts have been found for Akoya Biosciences: Phenolmager.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 5 mentions in open access literature.

Listed below are recent publications. The full list is available at [SPARC SAWG](#) .

van Ravensteijn SG, et al. (2025) Cemiplimab in Locally Advanced or Metastatic Secondary Angiosarcomas (CEMangio): A Phase II Clinical Trial and Biomarker Analyses. Clinical cancer research : an official journal of the American Association for Cancer Research, 31(17), 3678.

Zhang T, et al. (2025) Tumour-associated macrophage infiltration differs in meningioma genotypes, and is important in tumour dynamics. Journal of experimental & clinical cancer research : CR, 44(1), 162.

Collet L, et al. (2025) Unraveling the Tumor Microenvironment and PD-L1 Expression across Tissue Types in High-Grade Serous Ovarian Cancer in the NeoPembrOV/GINECO Phase II Randomized Trial. Clinical cancer research : an official journal of the American Association for Cancer Research, 31(15), 3317.

Digomann D, et al. (2025) Soluble TIM-3 and galectin-9 predict survival in gastric and gastroesophageal junction cancer. iScience, 28(11), 113871.

Wang H, et al. (2024) Preclinical study and phase II trial of adapting low-dose radiotherapy to immunotherapy in small cell lung cancer. Med (New York, N.Y.), 5(10), 1237.